Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Pharmacy Times

09:39 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Pharmacy Times" found in our extensive news archives from over 250 global news sources.

More Information about Pharmacy Times on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmacy Times for you to read. Along with our medical data and news we also list Pharmacy Times Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmacy Times Companies for you to search.

Showing News Articles 1–25 of 251 from Pharmacy Times

Friday 15th February 2019

Study: Drug Therapy Reduced Rate of Decline in Children with CLN2

The study was aimed at the efficacy and safety of cerliponase alfa (Brineura, BioMarin) for patients with CLN2.

Wednesday 13th February 2019

FDA Approves Treatment for Neglected Tropical Disease

Officials with the FDA have approved Novartis’ triclabendazole (Egaten) for the treatment of fascioliasis, also known as liver fluke infestation, in patients age 6 years and older.

Former House Speaker Scheduled to Speak at NACDS Meeting

Ryan, who was elected as the 54th Speaker of the House in 2015 and served in that role until January 2019 will speak as part of the Business Program, scheduled for Tuesday April 30.

New FDA Program Aims to Improve Quality, Innovation in Drug Development

An FDA program is seeking to facilitate better quality drug manufacturing through recognized consensus standards.

FDA Officials OK Generic Overactive Bladder Treatment

Camber recently announced the FDA approval of Tolterodine Tartrate ER capsules, a generic version of Detrol LA (tolterodine, Pharmacia & Upjohn).

Tuesday 12th February 2019

Split-Dosing Regimen Granted FDA Approval for Multiple Myeloma Treatment

Daratumumab was first approved in November 2015 as the first and only CD38-directed antibody for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to both. 

Pharmacists Are Happy With Their Salaries, Less So With Their Jobs, Survey Shows (Part 2)

Although many pharmacists are divided when it comes to their job satisfaction, most of them are currently happy with their compensation, according to a recent Pharmacy Times® Salary and Job Satisfaction Survey.

Monday 11th February 2019

Companies Reduce List Price for High Cholesterol Therapy

The collaborating drug companies cut prices in an effort to make their drugs more accessible.   

FDA Takes Action Against 17 Companies Claiming to Treat Serious Diseases

Warning letters and online advisory letters were posted to the agency's website for 58 products, mostly dietary supplements.

Sunday 10th February 2019

Researchers Predict Opioid Epidemic Will Grow

Researchers predict that the changing nature of the epidemic, driven by the illegal use of opioids such as heroin and fentanyl, has reduced the potential impact of programs that target prescription opioids.

Friday 8th February 2019

FDA Launches New Track-and-Trace Pilot Program

The program aims to reduce the amount of illegal or suspect prescription drugs distributed throughout the United States.

Thursday 7th February 2019

Directions in Pharmacy Meetings Announced for Spring 2019

Pharmacy Times Continuing Education™ (PTCE), a leader in continuing education for retail, health-system, managed care and specialty pharmacists, has announced the ninth annual Directions in Pharmacy® continuing education conference series, which will take place in 4 major cities across the United States in spring 2019.

Study Predicts Virtual Care to Expand in Upcoming Year

A recent study analyzed how health systems utilize and integrate virtual care into their daily practice.

Wednesday 6th February 2019

First Therapy Indicated for Rare Blood Clotting Disorder Granted FDA Approval

Officials with the FDA have approved caplacizumab-yhdp (Cablivi, Sanofi) injection for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting autoimmune disorder.  

Tuesday 5th February 2019

Regulatory Review Filings for 2 Antibacterial Agents Accepted by FDA

A New Drug Application (NDA) and a supplemental NDA (sNDA) were accepted for the Priority Review for products being developed by Merck.

Monday 4th February 2019

Recall Continuing for Seizure Treatment Drug

Dr. Reddy’s Laboratories is continuing its voluntary nationwide recall of the antiepileptic drug Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) in single-dose infusion bags to the hospital level in the United States.

Friday 1st February 2019

FDA Issues New Warning About Warfarin Test Strips

The FDA is warning patients and doctors that certain test strips used to monitor levels of the blood thinner warfarin may provide inaccurate results and should not be relied upon to adjust the drug dosage.

FDA Expands Drug's Label With Combo Therapy for First-Line NSCLC Treatment

Officials with the FDA have expanded the label of pemetrexed for injection (Alimta, Eli Lilly) in combination with pembrolizumab (Keytruda, Merck) and platinum chemotherapy.

Thursday 31st January 2019

Midwest Pharmacists Brave the Cold to Serve Patients

The 'polar vortex' that gripped much of the country this week has not stopped pharmacists from helping patients.

Wednesday 30th January 2019

Recall Expanded for Oral Suspension Drops

The affected lots have been found to contain levels of ibuprofen concentration that are higher than the specified limit.

FDA Approves Nasal Spray Treatment for Migraine

The FDA has approved sumatriptan nasal spray (Tosymra, Promius Pharma) for the acute treatment of migraine with or without aura in adults.  

Monday 28th January 2019

FDA Expands the Use of Ibrutinib to Include Combination for Certain Patients With CLL/SLL

The FDA has approved the use of ibrutinib (Imbruvica®, AbbVie) in combination with obinutuzumab (Gazyva®) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

New President Named for Independent Franchise Group

Health Mart has named Nimesh Jhaveri, MBA, RPh, its new president.

Monday 21st January 2019

Monday Pharmaceutical Mystery: January 21

Can you solve the pharmaceutical mystery? 

Friday 18th January 2019

FDA Announces Recall of Some Lots of Blood Pressure Medications

One lot of irbesartan and 7 lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare, a Prinston Pharmaceutical subsidiary are affected.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks